Preclinical evidence of ghrelin as a therapeutic target in epilepsy

Ge, Tongtong; Yang, Wei; Fan, Jie; Li, Bingjin

doi:10.18632/oncotarget.18349

Cited by 15 publications

(13 citation statements)

References 124 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, AG and UAG were downregulated in children affected by refractory epilepsy [17]. That gives the potential role played by these neuropeptides as anticonvulsants; such properties could be linked to epileptic patients and especially intractable seizures [18].…”

Section: Discussionmentioning

confidence: 95%

“…Ge and colleagues [18] supposed the possible mechanisms of ghrelin's anticonvulsant properties in the subsequent three features: firstly, Ghrelin can reduce cognitive dysfunction in epileptogenesis by endorsing hippocampal synaptic plasticity. Secondly, ghrelin applies anticonvulsant effectiveness via thought-provoking secretion of neuropeptide Y (NPY) which is one of the most studied neuropeptides in epilepsy.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serum and urine ghrelin in adult epileptic patients

Mohamed

Nageeb

Elsaid

2019

Egypt J Neurol Psychiatry Neurosurg

View full text Add to dashboard Cite

Background: Several neuropeptides have concerned with epilepsy pathogenesis; ghrelin showed an anticonvulsant effect. There is a potential relation between its level and antiepileptic drug (AEDs) response.Objective: To evaluate ghrelin effect in adult epileptic patients and in response to AEDs. Materials and methods: This case control study included 40 adult epileptic patients and 40 healthy controls. Participants were subjected to history taking of seizure semiology, full general and neurological examination, electroencephalography, and cranial imaging. Fasting serum acylated ghrelin (AG), unacylated ghrelin (UAG), and urine AG levels were estimated to all participants by enzyme-linked immunosorbent assay (ELIZA).Results: Serum AG, UAG, and urine AG levels were statistically higher in epileptic patients than controls (p = 0.005, 0.003, and 0.018 respectively). A significant higher level of serum AG was found among generalized epileptic patients (p = 0.038). There was higher statistically significant levels of all measured parameters among poly therapy patients (p = 0.003, 0.013, and 0.001 respectively). Also, a higher statistical significant level of serum AG and UAG in AEDs-responsive patients was found (p < 0.001). Our results demonstrated significant positive correlation between all measured parameters (serum AG, UAG, and urine AG) and epilepsy duration (p = 0.001, 0.002, and 0.009 respectively). High serum AG and UAG levels were independently associated with longer epilepsy duration (p = 0.00 and 0.008) and better response to AEDs (p < 0.001). Conclusion: These results indicated that serum AG and UAG levels were significantly high in epileptic patients especially with prolonged epilepsy duration and good AEDs response.Trial registration: ClinicalTrials.gov NCT03926273 (22-04-2019) "retrospectively registered."

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

Serum and urine ghrelin in adult epileptic patients

Mohamed

Nageeb

Elsaid

2019

Egypt J Neurol Psychiatry Neurosurg

View full text Add to dashboard Cite

show abstract

“…Epilepsy is a common chronic neurological disease characterized by the occurrence of recurrent and unprovoked seizures [ 1 ]. Of the more than 70 million people around the world suffering from diverse types of epilepsy [ 2 ], approximately 30% are resistant to therapy with currently available traditional antiepileptic drugs (AEDs) and, thus, still have frequent seizures [ 3 ]. As such, novel and effective therapeutic targets for the development of innovative AEDs are needed.…”

Section: Introductionmentioning

confidence: 99%

The role of substance P in epilepsy and seizure disorders

Wang

Fan

et al. 2017

Oncotarget

Self Cite

View full text Add to dashboard Cite

A range of evidence implicates the neuropeptide substance P (SP), a member of the tachykinin family, in emotional behavior, anxiety, pain, and inflammation. Recently, SP has been implicated in susceptibility to seizures, for which a potential proconvulsant role was indicated. Indeed, antagonists of a specific SP receptor, neurokinin-1 receptor, were found to attenuate kainic acid (KA)-induced seizure activity. However, detailed mechanisms of SP regulation in epilepsy remain obscure. In this review, we summarize the present literature to expound the role of SP in epilepsy, and provide hypotheses for potential mechanisms.

show abstract

“…Emerging evidence from the literature consistently advocates the therapeutic potential of ghrelin as a novel strategy for the treatment of various metabolic and cardiovascular disorders. These include anorexia, sarcopenia, cardiomyopathy, CLI, inflammatory disorders, metabolic syndrome, epilepsy, and neurodegenerative disorders ( 54 – 60 ).…”

Section: Therapeutic Potential Of Angiogenic Factorsmentioning

confidence: 99%

Ghrelin, MicroRNAs, and Critical Limb Ischemia: Hungering for a Novel Treatment Option

et al. 2017

View full text Add to dashboard Cite

Critical limb ischemia (CLI) is the most severe manifestation of peripheral artery disease. It is characterized by chronic pain at rest, skin ulcerations, and gangrene tissue loss. CLI is a highly morbid condition, resulting in a severely diminished quality of life and a significant risk of mortality. The primary goal of therapy for CLI is to restore blood flow to the affected limb, which is only possible by surgery, but is inadvisable in up to 50% of patients. This subset of patients who are not candidates for revascularisation are referred to as “no-option” patients and are the focus of investigation for novel therapeutic strategies. Angiogenesis, arteriogenesis and vasculogenesis are the processes whereby new blood vessel networks form from the pre-existing vasculature and primordial cells, respectively. In therapeutic angiogenesis, exogenous stimulants are administered to promote angiogenesis and augment limb perfusion, offering a potential treatment option for “no option” patients. However, to date, very few clinical trials of therapeutic angiogenesis in patients with CLI have reported clinically significant results, and it remains a major challenge. Ghrelin, a 28-amino acid peptide, is emerging as a potential novel therapeutic for CLI. In pre-clinical models, exogenous ghrelin has been shown to induce therapeutic angiogenesis, promote muscle regeneration, and reduce oxidative stress via the modulation of microRNAs (miRs). miRs are endogenous, small, non-coding ribonucleic acids of ~20–22 nucleotides which regulate gene expression at the post-transcriptional level by either translational inhibition or by messenger ribonucleic acid cleavage. This review focuses on the mounting evidence for the use of ghrelin as a novel therapeutic for CLI, and highlights the miRs which orchestrate these physiological events.

show abstract

Preclinical evidence of ghrelin as a therapeutic target in epilepsy

Cited by 15 publications

References 124 publications

Serum and urine ghrelin in adult epileptic patients

Serum and urine ghrelin in adult epileptic patients

The role of substance P in epilepsy and seizure disorders

Ghrelin, MicroRNAs, and Critical Limb Ischemia: Hungering for a Novel Treatment Option

Contact Info

Product

Resources

About